Who makes 12% oxygen in N2 breathing?

12% oxygen in N2 breathing is developed by Medical University of Vienna.

What development phase is 12% oxygen in N2 breathing in?

12% oxygen in N2 breathing is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

12% oxygen in N2 breathing

Medical University of Vienna · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	12% oxygen in N2 breathing
Sponsor	Medical University of Vienna
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effect of Systemic Hypoxia and Hyperoxia on Retinal Oxygen Saturation (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

12% oxygen in N2 breathing CI brief — competitive landscape report
12% oxygen in N2 breathing updates RSS · CI watch RSS
Medical University of Vienna portfolio CI